Article
Author(s):
Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.
Fixed duration venetoclax (Venclexta/Venclyxto; AbbVie) combination regimens continue to demonstrate long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia (CLL) with co-existing conditions, as well as relapsed or refractory (R/R) CLL, according to updated long-term follow-up data from the phase 3 CLL14 and MURANO studies that will be presented at the European Hematology Association Annual Congress in Frankfurt, Germany.
"Results from the CLL14 and MURANO studies demonstrate the long-term benefits of fixed-duration venetoclax combinations for patients living with CLL," said Mariana Cota Stirner, MD, PhD, vice president, hematology, AbbVie, in the press release.
Investigators will present findings from a long-term analysis of the phase 3 CLL14 trial. During this study, investigators compared fixed-duration venetoclax plus obinutuzumab (Gazyva; Genentech) with chlorambuci (Leukeran; KG) plus obinutuzumab in previously untreated patients with CLL and co-existing conditions. At the 6-year follow-up:
The most commonly reported adverse events (AEs) were grade 3 neutropenia, thrombocytopenia, treatment-related infusion-related reaction, anemia, febrile neutropenia, pneumonia, and leukopenia.
"The latest findings show that patients can experience long-term disease control, 5 years after stopping treatment," said CLL14 study investigator Othman Al-Sawaf, MD, a hematologist-oncologist at the University Hospital Cologne in Germany, and study physician at the German CLL Study Group, in the press release.
Investigators will also present findings from a long-term analysis of the phase 3 MURANO trial. During this study, investigators compared fixed-duration venetoclax plus rituximab (Rituxan; Genentech) with bendamustine (Bendeka; Teva) plus rituximab for patients with R/R CLL. At the 7-year follow-up:
The most common AEs associated with the venetoclax-rituximab combination were neutropenia, diarrhea, upper respiratory tract infection, fatigue, and nausea.
"We are pleased to find that uMRD was associated with prolonged PFS in R/R CLL patients after 7 years," said study investigator John Seymour, director of the Integrated Hematology Department at the Peter MacCallum Cancer Center and the Royal Melbourne Hospital in Melbourne, Australia, in the press release.
Venetoclax is a highly selective first-in-class therapeutic that binds to and inhibits the B-cell lymphoma-2 (BCL-2) protein. Targeting BCL-2 can restore the apoptosis of cancer cells. It is being developed by AbbVie and Roche, with US commercialization by AbbVie and Genentech.
Seymour concluded that "these findings continue to support the use of treatment with venetoclax plus rituximab in this patient population."
Reference
AbbVie. AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients. News Release. June 9, 2023. Accessed on June 9, 2023. https://news.abbvie.com/news/press-releases/abbvies-venclyxtovenclexta-venetoclax-continues-to-show-sustained-progression-free-survival-pfs-in-chronic-lymphocytic-leukemia-cll-patients.htm
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency